Systemic gaps in BRCA research: Structural insights into DNA repair expose colonial legacies in cancer science and profit-driven precision medicine
Original framing: “Detailed DNA repair snapshots reveal how BRCA-linked cancer cells may survive” — Phys.org
The BRCA narrative is entangled with histories of racialized medicine, from the unethical use of Henrietta Lacks’ cells to the exploitation of Black women in clinical trials for breast cancer research. The 1994 discovery of BRCA1/2 was accelerated by corporate funding (e.g., Myriad Genetics’ patenting of BRCA tests), embedding profit motives into genetic research. Colonial medical practices, such as the Tuskegee Syphilis Study, created enduring mistrust in marginalized communities toward genetic research.
The structural snapshots of BRCA-linked DNA repair are not neutral scientific facts but artifacts of a biomedical-industrial complex that privileges molecular reductionism over systemic justice.
This framework emerged from colonial legacies of exploitation (e.g., HeLa cells, San DNA patents) and is perpetuated by profit-driven research agendas that frame cancer as a technical problem solvable by expensive therapies, not as a symptom of environmental racism and healthcare apartheid. Indigenous epistemologies—from Māori *kaitiakitanga* to African bioethics—offer radical alternatives, emphasizing relational health and collective well-being over individual genetic fixes. The trickster’s gaze reveals the absurdity of a system that spends billions on gene-editing while neglecting carcinogen regulation or community-led prevention. True progress demands decolonizing research, centering marginalized voices, and reimagining cancer care as a convergence of scientific rigor, environmental justice, and cultural sovereignty.